Merck (MRK) Tops Q1 EPS by 5c; Raises Outlook

May 2, 2017 6:46 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Merck (NYSE: MRK) reported Q1 EPS of $0.88, $0.05 better than the analyst estimate of $0.83. Revenue for the quarter came in at $9.4 billion versus the consensus estimate of $9.25 billion.

  • First-Quarter 2017 Worldwide Sales Were $9.4 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange
  • First-Quarter 2017 GAAP EPS Was $0.56; First-Quarter Non-GAAP EPS Was $0.88
  • Company Narrows and Raises 2017 Full-Year Revenue Range to be Between $39.1 Billion and $40.3 Billion, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange
  • Company Narrows and Raises 2017 Full-Year GAAP EPS Range to be Between $2.51 and $2.63; Narrows and Raises 2017 Full-Year Non-GAAP EPS Range to be Between $3.76 and $3.88, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange
  • KEYTRUDA Development Program Advances with Two Additional Regulatory Approvals and CHMP Positive Opinion; Four sBLAs Currently Under Priority Review with PDUFA Action Dates in Second Quarter

GUIDANCE:

Merck sees FY2017 EPS of $3.76-$3.88, versus the consensus of $3.81. Merck sees FY2017 revenue of $39.1-40.3 billion, versus the consensus of $39.72 billion.

For earnings history and earnings-related data on Merck (MRK) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings

Related Entities

Earnings, PDUFA